AUDIENCE & REACH
Access an unrivalled network of trusted scientific brands

OUR PORTFOLIO*

3,000+ JOURNALS
7 MILLION+ ARTICLES

Our journals rank #1 in 37 Categories

OUR MONTHLY DIGITAL REACH**

133 MILLION page views
76 MILLION sessions

230,000+ third party email subscribers
700,000+ alerts subscribers

OUR AUDIENCE IS HIGHLY QUALIFIED AND INFLUENTIAL***

87% hold postgraduate qualifications
$85.8K average annual budget for research products/equipment
PARTNERING SOLUTIONS

BioPharma Dealmakers is an online platform, print publication, and webcast format specifically designed to appeal to industry scientists, partnering and licensing executives, and the investment community. Get started now at biopharmadealmakers.nature.com

PRINT

Published quarterly inside Nature Biotechnology and Nature Reviews Drug Discovery, BioPharma Dealmakers provides your company with the associated benefits of being profiled in Nature-branded publications. Enjoy enduring visibility with a high-profile audience, and the expert support of our editorial team.

PRINT PROFILE FEATURES

- Custom profile
- Distributed with high-impact journals:
  - Nature Biotechnology
  - Nature Reviews Drug Discovery
- Access to world-renowned editors

PRINT PROFILE BENEFITS

- Enduring visibility
- Quality association
- Exposure to biotech industry
- Exposure to drug discovery industry
- Expert editorial and design support

Korea Drug Development Fund
www.kddf.org

Propelling Korea’s oncology science globally

The Korea Drug Development Fund (KDDF) is a government-funded organization that supports early-stage translational research and development of biopharmaceuticals to translate scientific advances into clinical candidates to established biopharma companies aiming to translate scientific advances into clinical.

VCN Biosciences is developing a portfolio of its own anti-cancer programs, including one called VCN-01, focusing on different tumor indications. The company’s experienced team is currently reviewing 590 proposals and backed 162 programs. Of those programs, 46 have been the subject of KDDF’s achievements.

CONTACT
Email: kddf_bd@kddf.org
Seoul, Korea
Korea Drug Development Fund
www.kddf.org

Oncolytic adenovirus VCN-01 turns cold tumors hot

VCN Biosciences is developing a portfolio of its own anti-cancer programs, including one called VCN-01, focusing on different tumor indications. The company’s experienced team is currently reviewing 590 proposals and backed 162 programs. Of those programs, 46 have been the subject of KDDF’s achievements.

CONTACT
Email: kddf_bd@kddf.org
Seoul, Korea
Korea Drug Development Fund
www.kddf.org

Media Kit 2020 | BioPharma Dealmakers | 3
**PARTNERING SOLUTIONS**

**DIGITAL**

The BioPharma Dealmakers website is the premier partnering destination for life sciences companies and the investment community. Your digital profile amplifies the momentous impact created by your printed feature, and unlocks powerful networking tools and industry insights through a range of membership benefits.

**DIGITAL PROFILE FEATURES**
- Custom profile
- Industry intelligence
- Engagement tools
- Profile enhancements
- Visibility perks
- Account insights

**DIGITAL PROFILE BENEFITS**
- Rapid access to information
- Stay ahead of the competition
- Connect with investors
- Increase effectiveness
- Enhance prominence
- Strengthen your profile with supplemental media

**WEBCAST**

A BioPharma Dealmakers webcast compliments your digital and print presence with a powerful multimedia solution that enables your audience to interact with key people within your organization.

“The webcast was a valuable experience and it helped to raise awareness about our company. We were very happy with the number of attendees and questions from viewers during the webcast.” - Mary Marolla, PR Manager, OncoSec Medical

**WEBCAST BENEFITS**
- Generate a highly-targeted and qualified leads list
- Participate in genuine discussions with your target audience
- Maximize your visibility with branding on all marketing
- Raise your company’s profile to key opinion leaders
- Position your company as a key player in its field to potential partners, customers and investors

**Previous webcast topics have included:**
- Fighting infectious diseases
- Making a name in cancer immunotherapy
- New innovations in drug delivery technology
- Advances in precision medicine and genomic sequencing
- Innovating for ophthalmic diseases

**WEBCAST REGISTRANTS**

**WEBCAST AUDIENCE**

**Registrant Industry**

- 49% Pharma
- 16% Biotech
- 11% Investors/Venture Capital/Family Offices
- 8% Academia/Hospitals/Non-profits/Government
- 16% Service Providers/Other (e.g. media, consultancy, legal)

**Registrant Location**

- 51% Americas
- 27% Asia/RoW
- 21% UK/Europe

*Publisher Data 2019 | **Publisher Data 2017

Visit nature.com/webcasts
EXPLORE OUR AUDIENCE

Make successful connections with senior-level executives, business development leaders, potential clients and research professionals by creating an account with BioPharma Dealmakers. All issues of BioPharma Dealmakers will appear in Nature Biotechnology and Nature Reviews Drug Discovery, in print and freely accessible online. Issues of BioPharma Dealmakers are also distributed at key partnering and investor events.*

**GLOBAL AUDIENCE**

**JOURNAL METRICS**

**GLOBAL AUDIENCE**

**JOURNAL METRICS**

**GLOBAL AUDIENCE**

**JOURNAL METRICS**

**GLOBAL AUDIENCE**

Nature Biotechnology publishes new concepts in technology/methodology of relevance to the biological, biomedical, agricultural and environmental sciences as well as covers the commercial, political, ethical, legal, and societal aspects of this research.*

Nature Reviews Drug Discovery informs researchers of the science and business within the pharmaceutical and drug research industries.*

**TOP PLACE OF WORK**

**MEMBERS LOCATION**

**AVERAGE SITE VIEWS PER MONTH***

Print

Print

Print

Total Cites: 60,971
Industry Rank: 2/162

Total Cites: 32,266
Industry Rank: 1/267

Total Cites: 10,031
Industry Rank: 10,031

Print circulation

Print circulation

Print circulation

Print readership

Print readership

Print readership

Nature Biotechnology

nature.com/nbt

Nature Reviews Drug Discovery

nature.com/nrddd

**COMBINED READER PROFILE**

**TOP JOB FUNCTIONS**

**MEMBERS LOCATION**

**AVERAGE SITE VIEWS PER MONTH***

University/College 50%

Research Institute 23%

Industry/Corporation 8%

Hospital/Medical school 7%

Government 3%

Top Job Functions

Research/Labs 44%

Academic 37%

Clinicians/Healthcare 5%

Business/Investment 4%

Members Location

AMERICAS 47%

ASIA/ROW 28%

UK/EUROPE 25%
Editorial features focus on the partnering landscape, burgeoning therapeutic areas and geographical regions of interest.

**BIOPHARMA DEALMAKERS 2020 EDITORIAL CALENDAR**

<table>
<thead>
<tr>
<th>Issue Date</th>
<th>Editorial Themes</th>
<th>Conference Distribution*</th>
<th>Booking Deadline</th>
</tr>
</thead>
<tbody>
<tr>
<td>March</td>
<td>Oncology</td>
<td></td>
<td>January 8</td>
</tr>
<tr>
<td></td>
<td>Biopharma deals/Industry insights</td>
<td></td>
<td></td>
</tr>
<tr>
<td>June</td>
<td>Infectious diseases and vaccines</td>
<td></td>
<td>March 19</td>
</tr>
<tr>
<td></td>
<td>Biopharma deals/Industry insights</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Regenerative medicine (curative biologics, gene and cell therapies)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>September</td>
<td>Immuno-oncology</td>
<td>BioPharm America (September 11-12, Boston, USA)</td>
<td>June 18</td>
</tr>
<tr>
<td></td>
<td>Antibody technologies</td>
<td>NLS Days (September 8-10, Malmo, Sweden)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Central nervous system diseases</td>
<td>Bio-Europe (October 26-28, Munich, Germany)</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Society for Neuroscience annual meeting (October 24-28, USA)</td>
<td></td>
</tr>
<tr>
<td>December</td>
<td>Cardiovascular and respiratory diseases</td>
<td>JP Morgan/Biotech Showcase (2021 San Francisco, USA)</td>
<td>September 18</td>
</tr>
<tr>
<td></td>
<td>Inflammation-based diseases</td>
<td>BIO CEO &amp; Investors Conference</td>
<td></td>
</tr>
<tr>
<td></td>
<td>(microbiome, gastrointestinal, dermatology)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Deals round up of 2020</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*Conference distribution is subject to change. Contact your Account Manager for up-to-date information.
Contact us
biopharmadealmakers.nature.com

Claire Thompson
Head of Business Development
+44 207 418 5708
c.thompson@nature.com

Veronica Zacatenco
Business Development Manager
+1 212 451 8573
veronica.zacatenco@us.nature.com

Carmen Ramirez
Account Executive
+1 212 451 8472
carmen.ramirez@us.nature.com

Rebecca Djaic
Account Executive
+44 739 231 5386
Rebecca.djaic@springernature.com